ArticleCancer epidemiology2013
Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer.
Article in Cancer epidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates.Oncotarget · 2015Pooled it
- HOXB13, a high-risk prostate cancer gene, also confers risk for breast cancer: novel variants of clinical significance, especially in hormone-positive patients.Journal of human genetics · 2026Article
- Review
- Clinicopathological Characteristics and Mutational Landscape ofCurrent issues in molecular biology · 2023Article
- Molecular implications of HOX genes targeting multiple signaling pathways in cancer.Cell biology and toxicology · 2022Review
- Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population.Hereditary cancer in clinical practice · 2022Article
- Gene expression analysis in endometriosis: Immunopathology insights, transcription factors and therapeutic targets.Frontiers in immunology · 2022Article
- Massive parallel sequencing in individuals with multiple primary tumours reveals the benefit of re-analysis.Hereditary cancer in clinical practice · 2021Article
- The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites.Cancer epidemiology · 2020Article
- Article
- Paralogous HOX13 Genes in Human Cancers.Cancers · 2019Review
- Review
- The Enigmatic HOX Genes: Can We Crack Their Code?Cancers · 2019Review
- Role of HOX Genes in Stem Cell Differentiation and Cancer.Stem cells international · 2018Review
- HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions.Genes & diseases · 2017Article
- HOX genes: Major actors in resistance to selective endocrine response modifiers.Biochimica et biophysica acta · 2016Review
- The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.Oncotarget · 2015Article
- Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients.PloS one · 2015Article
- Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort.PLoS genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
Abstract
introductionThe HOXB13 pGly84Glu mutation has recently been associated with an increased risk of prostate cancer but the association of other cancer sites with this allele has not been assessed. Data has suggested that HOXB13 expression levels are decreased in colorectal cancer (CRC) cell lines indicating this gene may be involved in colorectal tumourigenesis.
methodsTo evaluate a potential association of this mutation with CRC, we genotyped the mutation in 2695 CRC cases and 4593 controls from population-based registries in Canada and Australia.
resultsThe HOXB13 pGly84Glu mutation was more common in CRC cases than controls (0.48% vs. 0.17%, P=0.02) indicating a significant association between the HOXB13 variant and CRC risk (OR=2.8; 95%CI: 1.2-6.8). This association was attenuated but remained significant with the inclusion of previously published and publicly available genotype data. Pedigree analysis of cases and controls revealed that 7/21 HOXB13 mutation carriers had a family history of prostate cancer. DISCUSSION: This report is the first to suggest a risk of CRC associated with mutations in the HOXB13 gene. These findings require further validation but may be of importance in the screening and genetic counseling of families known to carry the HOXB13 pGly84Glu mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.